"For too long, the Parkinson's community has had limited treatment options for advanced disease," Dr. Robert A. Hauser, professor of neurology at the University of South Florida said in a press ...

has guidelines on different drug therapy options to help patients with early-stage Parkinson’s disease control motor symptoms. Dopamine can’t be taken directly as a treatment because it’s ...

Neurologist Jason Aldred helped conduct trials for the device in Spokane through his work at Selkirk Neurology, where he ...

Anticholinergics and injection of botulinum toxin into the salivary glands are therapeutic options ... the treatment of erectile dysfunction in PD. Clinical diagnosis of Parkinson's disease ...

"For too long, the Parkinson's community has had limited treatment options for advanced disease," Robert Hauser, MD, MBA, of the University of South Florida in Tampa, said in an AbbVie news release.

The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with advanced Parkinson’s disease. This novel treatment is the first of its ...

The treatment allows patients to have a steady flow of dopamine that is needed to cope with the tremors, stiffness and slow movement that often comes with Parkinson’s disease.

Parkinson’s Disease and the Flu Shot: Advice From an Expert Having Parkinson’s disease makes getting an annual flu shot even more important for maintaining good health. Learn... Parkinson’s ...

including thrashing and other sudden movements Change in blood pressure Parkinson's disease has no cure, but there are treatment options to control your symptoms and improve your quality of life ...

About 1 million people in the U.S. are living with Parkinson's disease, with most developing symptoms after ... If that's the case, there are other options you can explore. Board and care homes offer ...

Among the symptoms, losing one's sense of smell could be an easily missed early indicator. The University of Auckland ...

Shares in MeiraGTx rose after the company said it received positive data in a clinical bridging study of AAV-GAD for the treatment of Parkinson's disease. Shares were up nearly 14% in premarket ...